Sponsor Pipeline

SCRI Development Innovations, LLC Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
6
Recruiting
5
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-04 NCT07637578
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory…
Recruitment opened
2026-08-04 NCT07637578
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory…
Trial sites expanded: 0 -> 3 locations
Active Trials by Phase
Phase 2
6
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT05748834 Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor… Breast Cancer Recruiting
NCT05972135 Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma Multiple Myeloma Recruiting
NCT06773910 BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer… Limited Stage Small Cell Lung Cancer Recruiting
NCT06974786 Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable… Multiple Myeloma, Newly Diagnosed Recruiting
NCT07011576 A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With… Colon Cancer Recruiting
NCT07637578 A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory… Multiple Myeloma (MM) Recruiting
Disease Areas
Get alerts when SCRI Development Innovations, LLC's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free